The stock of genetic testing company GeneDx Holdings (NASDAQ: WGS) was quite the hot item on the second trading day of the week. After the company published an encouraging second-quarter earnings report, investors piled into its shares to boost them to a more than 8% gain. That looked especially good next to the 0.3% slump of the benchmark S&P 500 index.
That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue. That was 49% higher year over year and was helped greatly by a 69% improvement in the sales of exome and genome testing services, which hit a total volume of 23,102.
Image source: Getty Images.